Skip to main content
. 2023 Jul 27;16:83. doi: 10.1186/s13045-023-01482-w

Fig. 1.

Fig. 1

Schematic representation of TCE and NKCE formats approved or in clinical development for hematological malignancies. Five of them are marketed as of July 2023: blinatumomab (Blincyto®), mosunetuzumab (Lunsumio®), teclistamab (Tecvayli®), epcoritamab (Epkinly®) and glofitamab (Columvi®). Additionally, elranatamab and talquetamab are under review, and odronextamab and linvoseltamab are in late-stage clinical trials